Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2394 Neoplasms 1813 Carcinoma, Non-Small-Cell Lung 1596 Prostatic Neoplasms 1296 Colorectal Neoplasms 1138 Lung Neoplasms 981 Neoplasm Metastasis 830 Multiple Myeloma 791 Leukemia, Myeloid, Acute 767 Ovarian Neoplasms 674 Pancreatic Neoplasms 661 Melanoma 659 Squamous Cell Carcinoma of Head and Neck 584 Carcinoma, Hepatocellular 566 Recurrence 562 Brain Neoplasms 526 Glioblastoma 512 Head and Neck Neoplasms 500 Stomach Neoplasms 497 Triple Negative Breast Neoplasms 464 Lymphoma 453 Uterine Cervical Neoplasms 449 Carcinoma, Renal Cell 423 Precursor Cell Lymphoblastic Leukemia-Lymphoma 410 Lymphoma, Non-Hodgkin 388 Endometrial Neoplasms 381 Sarcoma 368 Lymphoma, Follicular 356 Urinary Bladder Neoplasms 354 Hematologic Neoplasms 351

Interventions

liposomal doxorubicin 1 defactinib 1 Paclitaxel 1 Letrozole 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Low Grade Serous Ovarian Cancer × 1 year × Clear all

NCT06072781 2026-04-02

RAMP 301

Verastem, Inc.

Phase 3 Recruiting

Low Grade Serous Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡